Nov21761 Best Neurological Medical Diagnosis Solution 2021: IQ™ AINOSTICS, since 2019, has secured more than $5 million in funding for its AI based diagnostics technology. With each dollar being extremely well-earned, this company has garnered notoriety through its dedication to consistent innovation and betterment, creating a solution that is able to detect neurological condition risk with incredible accuracy and accruing prestigious and non-dilutive grants from sources such as Innovate UK as a result. Being an award-winning artificial intelligence specialist, AINOSTICS has made a name for itself by enabling analytics and diagnostics to be made through its exemplary technological solutions. A UK-based firm, it has been commercialising over two decades of world-leading research over the years that it has been in operation, its founding team carrying out the research into diagnosis of various neurological conditions personally in their capacity as renowned scientific advisors, and well-accredited researchers. Diagnosing conditions such as dementia, multiple sclerosis, stroke, brain tumours, traumatic brain injury, and more, it is influencing the medical industry in the furtherment of changing these diagnostic categories so that they can be better translated into real clinical situations. A new sufferer of neurological damage and injury is afflicted, on average, every seven seconds. This, in short, is what AINOSTICS focuses on, ensuring these people get diagnosed quickly and efficiently so that life saving treatment can be administered in a far shorter time frame than has previously been allowed, utilising its innovative AI solution – the Inference and Quantification Engine, or IQ – to seamlessly perform multimodal data fusion and analyses, making it possible to combine information from sources such as medical images, patient records, genomic profiles and fluid biomarkers, generating powerful hyperparameters that act as a signature for the pathological process. Critically, this enables clinicians to benefit from highly accurate disease diagnosis, stratification, staging, and outcome, such as in the cases of dementia; using only standard, non-invasive T1 MRI scans, IQ was able to predict the occurrence of Alzheimer’s disease in individuals who at the time had no symptoms with 92% accuracy up to 7 years later. AINOSTICS has thusly represented a true breakthrough in the healthcare industry in which affordable, automated, extensible, and personalised healthcare can be offered in a manner that is far less labour intensive, setting itself in good stead to becoming the global leader for remote monitoring solutions. Furthermore, it is dedicated to constant growth and development. Its breakthroughs up until this point have been monumental, but it never wishes to rest on its laurels, instead working hard to push the envelope and develop the next best thing, its staff making each of its market-leading solutions possible through hard work and tenacity. After all, it is its staff that have allowed it to pull through the trails of Covid-19, hitting some significant milestones despite the tumult and looking forward to increasing the velocity of its current growth path in 2022, setting up new clinical collaborations and starting a very exciting UK based clinical pilot test. Company: AINOSTICS Contact: Katherine Benton Website: ainostics.com Being an award-winning artificial intelligence specialist, AINOSTICS has made a name for itself by enabling analytics and diagnostics to be made through its exemplary technological solutions.
RkJQdWJsaXNoZXIy NTY1MjM3